Camilla Satragno
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Camilla Satragno has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
- D. Esposito
Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy
2 shared publications - Elisa Bennicelli
Division of Medical Oncology 2; IRCCS Ospedale Policlinico San Martino , Genova , Italy
2 shared publications - Eugenia Cella
Department of Internal Medicine and Medical Specialties (DIMI), School of Medicine, University of Genova , Genova
2 shared publications F Giannelli
Division of Radiotherapy; IRCCS Ospedale Policlinico San Martino , Genoa , Italy
2 shared publicationsL Barletta
Department of Neuroradiology; IRCCS Ospedale Policlinico San Martino , Genova , Italy
2 shared publications- Liliana Belgioia
U.O. Radioterapia Oncologica, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy
2 shared publications
Latest Publications
- Open Access
- 1 July 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 10 (3) , e2600091
Influence of Fractionation and Beam Sequencing on Absorbed Dose to Circulating Lymphocytes During Ultra-High Dose Rate and Conventional Radiotherapy: An In Silico Study
PURPOSE: Several in silico models concluded that ultra-high dose rate (UHDR) radiotherapy could spare large quantities of circulating lymphocytes. However, preclinical studies failed to show a reduction in radiation-induced lymphopenia after UHDR irradiation compared with conventional dose rates (CONV). This study aims to investigate the influence of fractionation and beam sequencing on absorbed dose to circulating lymphocytes during CONV and UHDR irradiations. MATERIALS AND METHODS: The LymphoDose framework was applied to a cohort of 162 patients treated for brain tumors with 3D conformal radiotherapy. Four scenarios of UHDR treatment were compared: (S1) one fraction with all beams delivered simultaneously, (S2) one fraction with sequentially delivered beams, (S3) three fractions with all beams delivered simultaneously, and (S4) three fractions with sequentially delivered beams. RESULTS: UHDR fractionation and the beam delivery scheme had a significant impact on irradiated blood volume (1.3% ± 0.1% for S1 v 13% ± 3.2% for S4) and lymphocyte pool (12.5% ± 0.1% for S1 v 32.8% ± 0.2% for S4). UHDR scenarios primarily irradiate lymphocytes through exposure of head-and-neck lymph node rather than circulating blood. CONV and UHDR result in distinct temporal dose patterns for lymphocytes, characterized by either numerous low-dose fractions or a few high-dose pulses. CONCLUSION: The doses delivered to lymphoid organs account for a substantial portion of the total dose received by the lymphocyte pool, showing only a limited difference between UHDR and CONV in terms of lymphocyte exposure. The fractionation strategy of UHDR irradiation beams could play an important role in successfully translating UHDR treatments into clinical practice.
- 1 July 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 10 (3) , e2600091
Open AccessInfluence of Fractionation and Beam Sequencing on Absorbed Dose to Circulating Lymphocytes During Ultra-High Dose Rate and Conventional Radiotherapy: An In Silico Study
PURPOSE: Several in silico models concluded that ultra-high dose rate (UHDR) radiotherapy could spare large quantities of circulating lymphocytes. However, preclinical studies failed to show a reduction in radiation-induced lymphopenia after UHDR irradiation compared with conventional dose rates (CONV). This study aims to investigate the influence of fractionation and beam sequencing on absorbed dose to circulating lymphocytes during CONV and UHDR irradiations. MATERIALS AND METHODS: The LymphoDose framework was applied to a cohort of 162 patients treated for brain tumors with 3D conformal radiotherapy. Four scenarios of UHDR treatment were compared: (S1) one fraction with all beams delivered simultaneously, (S2) one fraction with sequentially delivered beams, (S3) three fractions with all beams delivered simultaneously, and (S4) three fractions with sequentially delivered beams. RESULTS: UHDR fractionation and the beam delivery scheme had a significant impact on irradiated blood volume (1.3% ± 0.1% for S1 v 13% ± 3.2% for S4) and lymphocyte pool (12.5% ± 0.1% for S1 v 32.8% ± 0.2% for S4). UHDR scenarios primarily irradiate lymphocytes through exposure of head-and-neck lymph node rather than circulating blood. CONV and UHDR result in distinct temporal dose patterns for lymphocytes, characterized by either numerous low-dose fractions or a few high-dose pulses. CONCLUSION: The doses delivered to lymphoid organs account for a substantial portion of the total dose received by the lymphocyte pool, showing only a limited difference between UHDR and CONV in terms of lymphocyte exposure. The fractionation strategy of UHDR irradiation beams could play an important role in successfully translating UHDR treatments into clinical practice.
- Open Access
- 23 June 2026
- Published by Elsevier in EJC Paediatric Oncology
- Vol. 8
Scalp segmentation and permanent alopecia prediction in pediatric craniospinal irradiation: The PAST and HOPE projects
- 23 June 2026
- Published by Elsevier in EJC Paediatric Oncology
- Vol. 8
Open AccessScalp segmentation and permanent alopecia prediction in pediatric craniospinal irradiation: The PAST and HOPE projects
- Open Access
- 23 April 2024
- Published by Qeios Ltd
Review of: "Strategies for Management and Long-term Surveillance of Pediatric Differentiated Thyroid Cancer: Balancing Efficacy and Quality of Life"
GENERAL COMMENTS The author has undertaken a narrative review to discuss the management of pediatric differentiated thyroid cancer (DTC), focusing particularly on guidelines from China and the United States. The objective to provide a detailed overvi...
- 23 April 2024
- Published by Qeios Ltd
Open AccessReview of: "Strategies for Management and Long-term Surveillance of Pediatric Differentiated Thyroid Cancer: Balancing Efficacy and Quality of Life"
GENERAL COMMENTS The author has undertaken a narrative review to discuss the management of pediatric differentiated thyroid cancer (DTC), focusing particularly on guidelines from China and the United States. The objective to provide a detailed overvi...
- Open Access
- 29 September 2023
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 117 (2) , e485-e486
An Innovative Approach to Scalp Segmentation in Pediatric Brain Radiotherapy: An Atlas-Based Study
- 29 September 2023
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 117 (2) , e485-e486
Open AccessAn Innovative Approach to Scalp Segmentation in Pediatric Brain Radiotherapy: An Atlas-Based Study
- Open Access
- 1 September 2023
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 25 (Supplement) , ii77-ii78
P11.23.A GLIOBLASTOMA MOLECULAR CORRELATES OF SEIZURE OCCURRENCE/RECURRENCE AFTER SURGERY: THE ROLE OF P53 MUTATION
The integration of molecular data and histology changed the diagnostic approach and prognostic characterization for patients with brain tumors. The aim of this study is identify molecular risk factors associated with seizure occurrence and/or recurrence after surgery in patients with brain glioblastoma. Patients with brain glioblastoma were consecutively enrolled and underwent brain surgery, followed by histopathological and molecular evaluation. Immuno-histochemical, molecular (synaptophysin, GFAP, ATRX, p53, ki67 index and MGMT gene promoter methylation) and clinical (age, sex and seizure occurrence/recurrence before and/or after surgery) data were collected. Histopathological and molecular features were compared between patients with and without seizure occurrence/recurrence after surgery. A step-backward logistic regression was performed to investigate the association between molecular features and seizure occurrence/recurrence. 100 patients (age 59.51±1.23, 65 males) were enrolled. Forty-nine patients had seizures before surgery. After surgery, 40 patients (age 59.43±1.64, 27 males) had seizure occurrence/recurrence, while 60 (age 59.57±1.75, 38 males) had not. Patients with epilepsy (i.e., seizures before and/or after surgery) had lower synaptophysin (33.33%, p=0.008) and higher p53 (85%, p=0.038) mutation rate compared with patients without epilepsy. In the whole sample, seizure occurrence/recurrence after surgery was significantly associated with p53 mutation (OR: 3.9, CI 1.12-13.50, p=0.032) and seizure occurrence before surgery (OR: 5.3, CI 2.15-13.08, p<0.001). In patients without seizures before surgery, p53 mutation perfectly predicted seizure occurrence, therefore the OR was not computable. In fact, all patients without p53 mutation didn’t have seizure after surgery, while all patients that had seizure after surgery, also had p53 mutation (p=0.028). However, to note 71% patients with p53 mutation didn’t have seizure after surgery. The p53 mutation is related with a high risk of seizure occurrence/recurrence after surgery in brain glioblastoma, even in patients that didn’t have seizures before surgery. Conversely, the absence of p53 mutation appears to protect against the occurrence of seizures. If confirmed, this result may help in the management of anti-seizure treatment after surgery in brain glioblastoma patients.
- 1 September 2023
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 25 (Supplement) , ii77-ii78
Open AccessP11.23.A GLIOBLASTOMA MOLECULAR CORRELATES OF SEIZURE OCCURRENCE/RECURRENCE AFTER SURGERY: THE ROLE OF P53 MUTATION
The integration of molecular data and histology changed the diagnostic approach and prognostic characterization for patients with brain tumors. The aim of this study is identify molecular risk factors associated with seizure occurrence and/or recurrence after surgery in patients with brain glioblastoma. Patients with brain glioblastoma were consecutively enrolled and underwent brain surgery, followed by histopathological and molecular evaluation. Immuno-histochemical, molecular (synaptophysin, GFAP, ATRX, p53, ki67 index and MGMT gene promoter methylation) and clinical (age, sex and seizure occurrence/recurrence before and/or after surgery) data were collected. Histopathological and molecular features were compared between patients with and without seizure occurrence/recurrence after surgery. A step-backward logistic regression was performed to investigate the association between molecular features and seizure occurrence/recurrence. 100 patients (age 59.51±1.23, 65 males) were enrolled. Forty-nine patients had seizures before surgery. After surgery, 40 patients (age 59.43±1.64, 27 males) had seizure occurrence/recurrence, while 60 (age 59.57±1.75, 38 males) had not. Patients with epilepsy (i.e., seizures before and/or after surgery) had lower synaptophysin (33.33%, p=0.008) and higher p53 (85%, p=0.038) mutation rate compared with patients without epilepsy. In the whole sample, seizure occurrence/recurrence after surgery was significantly associated with p53 mutation (OR: 3.9, CI 1.12-13.50, p=0.032) and seizure occurrence before surgery (OR: 5.3, CI 2.15-13.08, p<0.001). In patients without seizures before surgery, p53 mutation perfectly predicted seizure occurrence, therefore the OR was not computable. In fact, all patients without p53 mutation didn’t have seizure after surgery, while all patients that had seizure after surgery, also had p53 mutation (p=0.028). However, to note 71% patients with p53 mutation didn’t have seizure after surgery. The p53 mutation is related with a high risk of seizure occurrence/recurrence after surgery in brain glioblastoma, even in patients that didn’t have seizures before surgery. Conversely, the absence of p53 mutation appears to protect against the occurrence of seizures. If confirmed, this result may help in the management of anti-seizure treatment after surgery in brain glioblastoma patients.
- Open Access
- 1 September 2023
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 25 (Supplement) , ii91-ii92
P11.71.B THE MULTIDISCIPLINARY METHOD TO DISTINGUISH TRUE TUMOUR PROGRESSION FROM PSEUDOPROGRESSION IN HIGH GRADE GLIOMA VIA THE SYSTEMIC INFLAMMATORY MARKERS
To identify the role of serum inflammatory markers and T1-gadolinium volume (T1GV) post-radiotherapy (RT), in the multidisciplinary approach to differentiate true tumor progression (TTP) from pseudo-progression (PsP) in high-grade glioma (HGG) patients. A retrospective cohort of HGG (WHO 2021) was consecutively enrolled from 2015 to 2021. Clinical, instrumental, and therapeutic data were collected at diagnosis, treatment and within 6 months after the end of RT.The response to treatment was assessed according to the modified RANO criteria; volumetry of suspected progression was performed on T1G and FLAIR. Blood tests also included the analysis of the neutrophil/lymphocyte ratio (NLR), systemic immune-inflammatory index (SII) and systemic inflammatory response index (SIRI). Patients with suspected progression underwent a new MRI within 3 months of the first one.Any association between the clinicopathological factors and the presence of progression were analysed by Chi-square and Fisher’s exact test. Differences between group in continuous variables were assessed by independent sample-T test or Mann-Whitney U test, as appropriate. Prognostic factors for progression were investigated with a regression logistic model where predictors were log-transformed owing to their skewed distribution. Due to an existing multicollinearity in the common multivariate regression model between the variables “NLR” and “SII index”, two further separate binary regression models were set up, whereby in the “Multivariate Model NLR” the SII index was not considered and in the “Multivariate Model SII index” the NLR was not included. A Cox regression analysis was conducted to assess the impact of PsP- and TTP-related factors on overall survival (OS). 39 patients (41.0% females) were included, 16 showed PsP and 23 TTP.NLR, SII and T1 gadolinium volume were higher in the TTP group than in PsP (respectively 4.7 vs 2.8, p= 0.002; 890.5 vs 546.5, p = 0.009; and 11.7 cm3 vs 2.2 cm3, pOR 2.7, CI 95% 1.3 to 5.5, p=0.006)] and SII [OR 4.2, 95%CI: 1.1 to 15.3, p=0.030].The OS was significantly worsened in patients with TTP compared to patients with PsP [HR 3.97, 95%CI: 1.59 to 9.93, p = 0.003]. At multivariate analysis other factors did not impact the overall survival. Higher NLR, SII and T1GV showed good sensitivity and specificity to differentiate between PsP and TTP.Further studies with larger cohorts are needed to evaluate the inclusion of inflammatory indices and volumetry in the differentiation diagram of PsP from TTP.
- 1 September 2023
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 25 (Supplement) , ii91-ii92
Open AccessP11.71.B THE MULTIDISCIPLINARY METHOD TO DISTINGUISH TRUE TUMOUR PROGRESSION FROM PSEUDOPROGRESSION IN HIGH GRADE GLIOMA VIA THE SYSTEMIC INFLAMMATORY MARKERS
To identify the role of serum inflammatory markers and T1-gadolinium volume (T1GV) post-radiotherapy (RT), in the multidisciplinary approach to differentiate true tumor progression (TTP) from pseudo-progression (PsP) in high-grade glioma (HGG) patients. A retrospective cohort of HGG (WHO 2021) was consecutively enrolled from 2015 to 2021. Clinical, instrumental, and therapeutic data were collected at diagnosis, treatment and within 6 months after the end of RT.The response to treatment was assessed according to the modified RANO criteria; volumetry of suspected progression was performed on T1G and FLAIR. Blood tests also included the analysis of the neutrophil/lymphocyte ratio (NLR), systemic immune-inflammatory index (SII) and systemic inflammatory response index (SIRI). Patients with suspected progression underwent a new MRI within 3 months of the first one.Any association between the clinicopathological factors and the presence of progression were analysed by Chi-square and Fisher’s exact test. Differences between group in continuous variables were assessed by independent sample-T test or Mann-Whitney U test, as appropriate. Prognostic factors for progression were investigated with a regression logistic model where predictors were log-transformed owing to their skewed distribution. Due to an existing multicollinearity in the common multivariate regression model between the variables “NLR” and “SII index”, two further separate binary regression models were set up, whereby in the “Multivariate Model NLR” the SII index was not considered and in the “Multivariate Model SII index” the NLR was not included. A Cox regression analysis was conducted to assess the impact of PsP- and TTP-related factors on overall survival (OS). 39 patients (41.0% females) were included, 16 showed PsP and 23 TTP.NLR, SII and T1 gadolinium volume were higher in the TTP group than in PsP (respectively 4.7 vs 2.8, p= 0.002; 890.5 vs 546.5, p = 0.009; and 11.7 cm3 vs 2.2 cm3, pOR 2.7, CI 95% 1.3 to 5.5, p=0.006)] and SII [OR 4.2, 95%CI: 1.1 to 15.3, p=0.030].The OS was significantly worsened in patients with TTP compared to patients with PsP [HR 3.97, 95%CI: 1.59 to 9.93, p = 0.003]. At multivariate analysis other factors did not impact the overall survival. Higher NLR, SII and T1GV showed good sensitivity and specificity to differentiate between PsP and TTP.Further studies with larger cohorts are needed to evaluate the inclusion of inflammatory indices and volumetry in the differentiation diagram of PsP from TTP.